immuno-chemotherapy
Showing 1 - 25 of >10,000
Esophageal Cancer Trial (Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B), Adjuvant chemoradiotherapy)
Not yet recruiting
- Esophageal Cancer
- Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)
- Adjuvant chemoradiotherapy
- (no location specified)
Dec 19, 2022
Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Measure of the circulating tumor DNA
-
Rouen, FranceCentre Henri Becquerel
Nov 17, 2023
Triple Negative Breast Cancer, Neoadjuvant Chemo, Pembrolizumab Trial in Seoul (Visium, Whole Genome Sequencing(WGS)/Whole
Recruiting
- Triple Negative Breast Cancer
- +3 more
- Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 15, 2023
NSCLC Stage III Trial (radiotherapy, Platinum-Based Drug, Immunotherapy)
Not yet recruiting
- Non-small Cell Lung Cancer Stage III
- radiotherapy
- +3 more
- (no location specified)
Sep 10, 2023
Stage III NSCLC, Locally Advanced, Unresectable Trial (standard Radiotherapy, Chemotherapy, Immunotherapy)
Not yet recruiting
- Stage III Non-small Cell Lung Cancer
- +2 more
- standard Radiotherapy
- +3 more
- (no location specified)
Oct 20, 2023
COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in
Not yet recruiting
- Follicular Lymphoma
- Cellular immunity vs SARS-CoV-2
- +6 more
-
Alessandria, IT, Italy
- +13 more
Oct 10, 2023
NSCLC Trial in Canada, United States (Pembrolizumab)
Active, not recruiting
- Non-Small Cell Lung Cancer
-
Baltimore, Maryland
- +5 more
Apr 7, 2022
Esophageal Adenocarcinoma Trial in Cologne, München (Durvalumab 50 MG/ML, Tremelimumab)
Recruiting
- Esophageal Adenocarcinoma
- Durvalumab 50 MG/ML
- Tremelimumab
-
Cologne, Germany
- +1 more
Feb 17, 2022
Acute Lymphoblastic Leukemia, Pediatric, ALL, Infants Trial (the risk-adapted choice of therapy and the use of a combination of
Not yet recruiting
- Acute Lymphoblastic Leukemia, Pediatric
- ALL, Infants
- the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
- (no location specified)
Aug 26, 2021
Gastric Adenocarcinoma, Oesophageal Adenocarcinoma Trial in London (FLOT-A)
Recruiting
- Gastric Adenocarcinoma
- Oesophageal Adenocarcinoma
-
London, United KingdomThe Royal Marsden Hospital
Mar 9, 2021
Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8 Trial in Houston
Recruiting
- Laryngeal Squamous Cell Carcinoma
- +2 more
- Carboplatin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 10, 2022
High-Risk Cancer, Locally Advanced Breast Cancer Trial in London (Neoadjuvant radiotherapy)
Recruiting
- High-Risk Cancer
- Locally Advanced Breast Cancer
- Neoadjuvant radiotherapy
-
London, Ontario, CanadaLondon Regional Cancer Program
Aug 11, 2021
Osteosarcoma Trial in France (Mifamurtide, EI or M-API regimen depending on patient age)
Recruiting
- Osteosarcoma
- Mifamurtide
- EI or M-API regimen depending on patient age
-
Amiens, France
- +30 more
Dec 8, 2022
Bladder Carcinoma Trial in Milano (Cabozantinib, Durvalumab)
Unknown status
- Bladder Carcinoma
-
Milano, ItalyFondazione IRCCS Istituto Nazionale Tumori
Feb 24, 2021
HIV, Burkitt's Lymphoma Trial in Italy (Induction Phase, Consolidation Phase (on day +50), Intensification phase)
Completed
- HIV
- Burkitt's Lymphoma
- Induction Phase
- +4 more
-
Aviano (PN), Italy
- +7 more
Aug 2, 2022
Immunotherapy in Locally Advanced or Oligometastatic NSCLC
Recruiting
- Carcinoma, Non-Small-Cell Lung
- induction therapy
-
Esslingen, GermanyKlinikum Esslingen
Aug 15, 2022
Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
- Toripalimab plus Chemotherapy
- (no location specified)
Jul 28, 2023
Metastatic Esophageal Squamous Cell Carcinoma Trial in Qingdao (TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1
Recruiting
- Metastatic Esophageal Squamous Cell Carcinoma
- TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
-
Qingdao, Shandong, China
- +1 more
Nov 13, 2023
Tumor, Plasma Cell, Lymphoma Trial in Toulouse (Comprehensive Geriatric Assessment)
Recruiting
- Neoplasm, Plasma Cell
- Lymphoma
- Comprehensive Geriatric Assessment
-
Toulouse, FranceUniversity Hospital Toulouse
Oct 12, 2022
NSCLC Trial in Marseille (Durvalumab (MEDI4736), Monalizumab (IPH2201), Oleclumab (MEDI9447))
Recruiting
- Non-small Cell Lung Cancer
- Durvalumab (MEDI4736)
- +5 more
-
Marseille, FranceAssistance Publique Hopitaux de Marseille
Sep 21, 2022
Pancreatic Cancer Trial (TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine,
Not yet recruiting
- Pancreatic Cancer
- TTX-030, nab-paclitaxel and gemcitabine
- +2 more
- (no location specified)
Nov 3, 2023
Lymphoma Trial in Germany, Israel (biological, drug, radiation)
Completed
- Lymphoma
- filgrastim
- +6 more
-
Amberg, Germany
- +78 more
Mar 9, 2021
DLBCL, DLBCL Germinal Center B-Cell Type, DLBCL, Not Otherwise Specified Trial in Columbus (Molecular Nanotechnology)
Recruiting
- Diffuse Large B-Cell Lymphoma
- +3 more
- Molecular Nanotechnology
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jun 2, 2022
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)
Not yet recruiting
- Recurrent Ovarian Cancer
- +2 more
- (no location specified)
Jul 26, 2022